DexCom Inc

DXCM: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$46.00KtsbXtjfpzhfl

DexCom Nears U.S. Launch of G7 and Potential Expansion of Its Patient Pool; Raising Our FVE

Business Strategy and Outlook

Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice of this CGM market, but a recent wave of innovation in the diabetes device market has intensified competitive pressure. Nonetheless, Dexcom has done a credible job of adapting and fending off competition from Abbott and Medtronic.

Sponsor Center